The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | The key unmet needs in the frontline and R/R setting in amyloidosis
Pedro Vianna, MD, Dana-Farber Cancer Institute, Boston, MA, emphasizes the importance of early diagnosis for patients with amyloidosis, which is preceded by monoclonal gammopathy of unknown significance (MGUS), and advocates for a multidisciplinary approach to manage the various organ systems affected by the disease. In relapsed/refractory (R/R) cases, Dr Vianna highlights the need for more precise criteria to define hematological relapse and suggests that novel treatments, such as venetoclax, bispecific antibodies, or anti-fibrillary therapies, show promise for treating these patients. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
